(5)
💡 Strategic Partnership at a Premium
Prevail Partners, LLC, a major U.S. life sciences fund, has taken a significant equity position in the company—at a 20% premium to the 30-day VWAP. (4)
This move reflects strong confidence in the
company’s groundbreaking science and ambitious vision.
But it doesn’t stop there. The company has also partnered with Prevail InfoWorks, Inc., a globally renowned Clinical Research Organization (CRO), to manage their next Phase 2 clinical trial. (4)
Recognized as a leader in tech-enabled clinical services, Prevail brings unmatched expertise to ensure efficient and impactful trial
execution.
🔬 Breakthrough Science in Action
At the center of this company’s success is MYMD-1®, an innovative oral drug targeting chronic inflammation and immune-metabolic dysregulation. Early results are already turning heads:
- Sarcopenia Success: Clinical trials met key endpoints, reducing chronic inflammatory markers without adverse effects.
- Expanding
Indications: Phase 2 trials are planned for rheumatoid arthritis and Hashimoto’s thyroiditis, creating exciting opportunities in new markets.
- Massive Opportunity: With no FDA-approved treatments for sarcopenia, the potential market represents billions annually, addressing critical unmet needs for millions of people. (1)(4)
